The Primary Objective of the Study is to Compare Eye Dryness Following LASIK (Laser-Assisted In Situ Keratomileusis) Surgery to Eye Dryness Prior to Receiving Perioperative Miebo in Patients With Dry Eye Disease (Sonoran)

Vance Thompson Vision

Status and phase: Enrolling; Phase 4

Conditions: Dry Eye Syndrome (DES); Dry Eye Disease (DED)

Treatments: Drug: Miebo four times per day

Study type: Interventional

Funder types: Other

Identifiers

NCT07650708

BL-RX01-SONORAN-1401

Details and patient eligibility

About

Compare eye dryness following laser-assisted in situ keratomileusis (LASIK) surgery to eye dryness prior to receiving perioperative Miebo in patients with dry eye disease (DED)

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Be at least 18 years of age at the time of consent, able to provide written voluntary informed consent, willing to follow instructions and participate in all trial assessments and visits
2. Be a candidate for routine, uncomplicated bilateral LASIK surgery (for spherical equivalent [≤-8.00D] myopia or myopic astigmatism correction, not combined with any other procedure; monovision myopic targets are allowed, however the myopic target eye will be the non-study [fellow] eye)
3. No history of refractive surgery including implantable Collamer lens (ICL) or cataract surgery
4. Total CFS score ≥1 and ≤6 using the National Eye Institute scale at Visit 1 (in at least one eye)
5. Ocular Surface Disease Index (OSDI) ≥13 and ≤22 at Visit 1

Exclusion criteria

1. Have any clinically significant ocular surface slit-lamp findings in the study eye that, in the opinion of the Investigator, could interfere with outcomes of a routine, uncomplicated LASIK surgery, including but not limited to:

   1. History of eye trauma/surgery within the last 6 months that resulted in corneal scarring
   2. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells, Stevens-Johnson syndrome, active blepharitis, or lid margin inflammation
   3. Abnormal cornea (e.g., keratoconus or corneal epithelial defect, pterygium, or history of herpetic keratitis)

2. Use of any of the following ocular therapies in the study eye within 30 days prior to Visit 1: topical ocular steroid treatments, prescription dry eye therapy (including nasal spray), or topical intraocular pressure-lowering medications

3. Use of any eye drops (prescription or over the counter) in the study eye within 24 hours prior to Visit 1

4. Use of any oral medications known to cause ocular drying (e.g., antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial

5. Had a LipiFlow®, intense pulsed light (IPL) therapy, etc. in the study eye within 3 months prior to Visit 1

6. Had received or removed a permanent punctum plug in the study eye within 1 month (3 months for dissolvable punctum plugs) prior to Visit 1

7. Have worn soft contact lenses within either 3 days prior to the study or rigid gas-permeable contact lenses for 1 month prior to Visit 1 or any planned wear during the study

8. Have undergone intraocular surgery or ocular laser surgery in the study eye within 3 months prior to Visit 1

9. Have ocular allergies that are/expected to be active during the trial period

10. Have active ocular or systemic infection (bacterial, viral, or fungal), including fever

11. Have any ocular findings or uncontrolled systemic disease that, in the opinion of the Investigator, will interfere with the trial

12. Female subjects who are pregnant, nursing, or planning a pregnancy

13. Female subjects of childbearing potential who are not using an acceptable means of birth control; acceptable methods of contraception include hormonal (oral, implantable, injectable, or transdermal) contraception; mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom) contraception; intrauterine device; or surgical sterilization of partner. For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.

14. Have a known allergy and/or sensitivity or lack of desired efficacy in response to the investigational drug

15. Are currently enrolled in an investigational drug or device study or had used an investigational drug or device within 30 days prior to Visit 1 -

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Miebo

Active Comparator group

Description:

Miebo instilled four times per day to each eye

Treatment:

Drug: Miebo four times per day